IP Library Granted Patent US 11,054,421
Granted Patent B2
US 11,054,421 · App. 16/600,317 · Granted Jul 6, 2021

Compositions, methods and kits to detect herpes simplex virus nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,054,421
App. No.
16/600,317
Granted
Jul 6, 2021
Kind
B2
Abstract

The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Herpes Simplex Virus (HSV) nucleic acid (e.g., HSV-1 and/or HSV-2 nucleic acid). Compositions include amplification oligomers, detection probe oligomers and/or target capture oligomers. Kits and methods comprise at least one of these oligomers.

Claims (20)

1. A Herpes Simplex Virus 1 (HSV-1) detection probe comprising a target-hybridizing sequence and a covalently linked non-nucleotide detectable label, wherein the target hybridizing sequence consists of the sequence of SEQ ID NO: 22.

2. The HSV-1 detection probe of claim 1 , further comprising a quencher.

3. The HSV-1 detection probe of claim 2 , which is a molecular torch.

4. The HSV-1 detection probe of claim 3 , comprising the sequence of SEQ ID NO: 21.

5. A Herpes Simplex Virus 2 (HSV-2) detection probe comprising a target-hybridizing sequence and a covalently linked non-nucleotide detectable label, wherein the target hybridizing sequence consists of the sequence of SEQ ID NO: 27.

6. The HSV-2 detection probe of claim 5 , further comprising a quencher.

7. The HSV-2 detection probe of claim 6 , which is a molecular torch.

8. The HSV-2 detection probe of claim 7 , comprising the sequence of SEQ ID NO: 26.

9. A combination comprising the HSV-1 detection probe of claim 1 and an HSV-2 detection probe comprising a target-hybridizing sequence and a covalently linked non-nucleotide detectable label, wherein the target hybridizing sequence of the HSV-2 detection probe consists of the sequence of SEQ ID NO: 27.

10. The combination of claim 9 , wherein the HSV-1 detection probe further comprises a quencher and the HSV-2 detection probe further comprises a quencher.

11. The combination of claim 10 , wherein the HSV-1 detection probe is a molecular torch and the HSV-2 detection probe is a molecular torch.

12. The combination of claim 11 , wherein the HSV-1 detection probe comprises the sequence of SEQ ID NO: 21 and the HSV-2 detection probe comprises the sequence of SEQ ID NO: 26.

13. A kit comprising the combination of claim 9 .

14. A kit comprising the combination of claim 12 .

15. A method of determining the presence or absence of Herpes Simplex Virus 1 (HSV-1) in a sample, said method comprising contacting a sample suspected of comprising HSV-1 nucleic acid with the HSV-1 detection probe of claim 1 and determining whether the HSV-1 detection probe hybridizes to the HSV-1 nucleic acid.

16. The method of claim 15 , wherein the HSV-1 nucleic acid is an HSV-1 amplification product and the HSV-1 detection probe is configured to specifically hybridize to the HSV-1 amplification product.

17. A method of determining the presence or absence of Herpes Simplex Virus 2 (HSV-2) in a sample, said method comprising contacting a sample suspected of comprising HSV-2 nucleic acid with the HSV-2 detection probe of claim 5 and determining whether the HSV-2 detection probe hybridizes to the HSV-2 nucleic acid.

18. The method of claim 17 , wherein the HSV-2 nucleic acid is an HSV-2 amplification product and the HSV-2 detection probe is configured to specifically hybridize to the HSV-2 amplification product.

19. A method of determining the presence or absence of HSV-1 or HSV-2 in a sample, said method comprising contacting a sample suspected of comprising HSV-1 or HSV-2 nucleic acid with the HSV-1 detection probe of claim 1 and an HSV-2 detection probe comprising a target-hybridizing sequence and a covalently linked non-nucleotide detectable label, wherein the target hybridizing sequence of the HSV-2 detection probe consists of the sequence of SEQ ID NO: 27; and determining whether the HSV-1 detection probe hybridizes to the HSV-1 nucleic acid and whether the HSV-2 detection probe hybridizes to the HSV-2 nucleic acid.

20. The method of claim 19 , wherein the HSV-1 nucleic acid is an HSV-1 amplification product and the HSV-1 detection probe is configured to specifically hybridize to the HSV-1 amplification product; and the HSV-2 nucleic acid is an HSV-2 amplification product and the HSV-2 detection probe is configured to specifically hybridize to the HSV-2 amplification product.

Assignments (4)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 12, 2021
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 057787/0526 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: GETMAN, DAMON KITTREDGE; AIYER, APARNA
To: GEN-PROBE INCORPORATED
Reel/Frame 056427/0843 →
SECURITY INTEREST Recorded Oct 15, 2020
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 054089/0804 →